Serratus Posterior Superior Intercostal Plane Block versus intrathekales Morphin bei VATS
Vergleich der Auswirkungen von Serratus-posterior-superior-Interkostalblock und intrathekalem Morphin auf postoperative akute Schmerzen bei Patienten, die sich einer videoassistierten thorakoskopischen Operation unterziehen
This study aims to compare the analgesic effects of the serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.
This is a prospective, randomized, controlled, single-center clinical trial including adult patients undergoing elective thoracoscopic surgery. Participants will be randomly assigned to receive either a serratus posterior superior intercostal plane block or intrathecal morphine before general anesthesia.
The primary outcome is cumulative opioid consumption during the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents. Secondary outcomes include pain scores, time to first analgesic request, quality of recovery, and postoperative complications.
The study aims to determine whether these two techniques differ in their effectiveness for postoperative pain management.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This study is a prospective, randomized, controlled, single-blinded, parallel-group clinical trial designed to compare the analgesic efficacy of serratus posterior superior intercostal plane block and intrathecal morphine in patients undergoing video-assisted thoracoscopic surgery.
Eligible patients aged 18-75 years with American Society of Anesthesiologists physical status I-III scheduled for elective thoracoscopic procedures (wedge resection, segmentectomy, or lobectomy) will be included. Patients will be randomized in a 1:1 ratio using a computer-generated sequence with block randomization.
Participants in the serratus posterior superior intercostal plane block group will receive an ultrasound-guided regional block prior to the induction of general anesthesia. Participants in the intrathecal morphine group will receive an intrathecal morphine injection before general anesthesia. All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia.
The primary outcome is cumulative opioid consumption within the first 24 postoperative hours, expressed as intravenous morphine milligram equivalents.
Secondary outcomes include opioid consumption at 12 hours, numeric rating scale pain scores at rest and during activity, time to first analgesic request, quality of recovery scores, postoperative nausea and vomiting, sedation levels, pruritus, respiratory depression, and postoperative complications up to 30 days.
This study aims to evaluate the relative effectiveness of these two analgesic techniques and to improve postoperative pain management strategies in thoracic surgery.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Samsun
-
Atakent, Samsun, Türkei (türkiye), 55270
- Ondokuz Mayis University
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age between 18 and 75 years
- American Society of Anesthesiologists physical status I to III
- Scheduled for elective video-assisted thoracoscopic surgery, including wedge resection, segmentectomy, or lobectomy
Exclusion Criteria:
- Refusal to participate
- Pregnancy
- Morbid obesity (body mass index greater than 40 kg per square meter)
- Allergy to study medications
- Neuropsychiatric disorders, cognitive impairment, or inability to communicate
- History of substance abuse
- Active systemic infection or infection at the planned injection site
- Severe cardiac, respiratory, hepatic, renal, or endocrine disease.
- Chronic pain syndrome or ongoing chronic pain treatment
- Emergency surgery or previous ipsilateral VATS or thoracotomy
- Preoperative opioid use: ≥15 mg oral morphine equivalents/day for ≥30 days within the previous 3 months.
- Anticipated need for postoperative mechanical ventilation.
- Contraindications to neuraxial or peripheral regional anesthesia, including anticoagulant therapy, coagulopathy, infection, or relevant anatomical abnormalities.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Intrathecal Morphine
Participants receive intrathecal morphine before induction of general anesthesia. Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine. |
Preservative-free morphine at 5 µg/kg based on ideal body weight is diluted with 0.9% saline to a total volume of 3 mL and administered intrathecally before induction of general anesthesia. |
|
Experimental: Serratus Posterior Superior Intercostal Plane Block
Participants receive an ultrasound-guided serratus posterior superior intercostal plane block before induction of general anesthesia. A total of 30 milliliters of 0.25 percent bupivacaine with epinephrine is administered into the interfascial plane between the serratus posterior superior muscle and intercostal muscles. All patients subsequently undergo standardized general anesthesia and receive postoperative patient-controlled analgesia with intravenous morphine. |
Ultrasound-guided serratus posterior superior intercostal plane block is performed before induction of general anesthesia using 30 milliliters of 0.25 percent bupivacaine with epinephrine injected into the interfascial plane between the serratus posterior superior muscle and intercostal muscles. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cumulative IV-MME during the first 24 hours after postoperative admission following extubation
Zeitfenster: 24 hours
|
Total opioid consumption during the first 24 postoperative hours is expressed as intravenous morphine milligram equivalents, including patient-controlled analgesia and rescue analgesia. |
24 hours
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cumulative IV-MME during the first 12 hours after postoperative admission following extubation
Zeitfenster: 12 hours
|
Total opioid consumption during the first 12 postoperative hours expressed as intravenous morphine milligram equivalents |
12 hours
|
|
Postoperative pain scores
Zeitfenster: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Pain intensity assessed using the 11-point Numeric Rating Scale (NRS; 0-10), where higher scores indicate greater pain intensity, with 0 representing no pain and 10 representing the worst imaginable pain, measured at rest and during activity. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Time to first patient-controlled analgesia demand
Zeitfenster: 24 hours
|
Time from postoperative admission to the first PCA morphine demand. |
24 hours
|
|
Quality of recovery score
Zeitfenster: Preoperative baseline, 24 hours postoperatively, and at discharge
|
Quality of recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15; total score range 0-150), a validated patient-reported outcome measure where higher scores indicate better postoperative recovery. |
Preoperative baseline, 24 hours postoperatively, and at discharge
|
|
Postoperative nausea and vomiting
Zeitfenster: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Postoperative nausea and vomiting (PONV) will be assessed using a 4-point ordinal scale (0-3), where 0 indicates no nausea or vomiting, 1 indicates nausea without vomiting, 2 indicates a single episode of vomiting, and 3 indicates multiple episodes of vomiting; higher scores indicate worse symptoms. Scores >1 will be treated with ondansetron 4 mg IV; persistent symptoms will be treated with intravenous metoclopramide. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Sedation level
Zeitfenster: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Sedation level assessed using the Ramsay Sedation Scale (RSS; 1-6), a validated ordinal scale where higher scores indicate deeper sedation, with 1 representing anxiety/agitation and 6 representing no response to stimuli. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Respiratory depression
Zeitfenster: 24 hours
|
Incidence of respiratory depression defined as oxygen saturation below 90 percent or respiratory rate below 8 breaths per minute |
24 hours
|
|
Pruritus
Zeitfenster: 0, 3, 6, 12, 18, and 24 hours postoperatively
|
Incidence and severity of postoperative pruritus assessed using a 4-point ordinal scale (0-3), where 0 = no pruritus, 1 = mild pruritus (itching without scratching), 2 = moderate pruritus (itching with scratching), and 3 = severe pruritus requiring treatment; higher scores indicate worse symptoms. |
0, 3, 6, 12, 18, and 24 hours postoperatively
|
|
Block-related complications
Zeitfenster: Up to 30 days postoperatively
|
Incidence of post-dural puncture headache, paresthesia, hematoma, and local anesthetic systemic toxicity associated with the study interventions. |
Up to 30 days postoperatively
|
|
Postoperative complications
Zeitfenster: 30 days
|
Postoperative complications assessed using the Clavien-Dindo classification, where higher grades indicate more severe complications. |
30 days
|
|
Remifentanil consumption
Zeitfenster: Intraoperative period (from induction to end of surgery), up to 4 hours
|
Total intraoperative remifentanil consumption administered during surgery, measured in micrograms (µg). |
Intraoperative period (from induction to end of surgery), up to 4 hours
|
|
Rescue analgesia requirement
Zeitfenster: 24 hours
|
Incidence of patients requiring additional analgesia beyond patient-controlled analgesia |
24 hours
|
|
Incidence of postoperative nausea and/or vomiting
Zeitfenster: 24 hours postoperatively
|
Incidence of postoperative nausea and vomiting (PONV), defined as the occurrence of at least one episode of nausea and/or vomiting within the first 24 hours postoperatively (yes/no). Patients experiencing at least one episode will be classified as having PONV. |
24 hours postoperatively
|
|
Propofol consumption
Zeitfenster: Intraoperative period (from induction to end of surgery), up to 4 hours
|
Total intraoperative propofol consumption administered during surgery, measured in milligrams (mg). |
Intraoperative period (from induction to end of surgery), up to 4 hours
|
|
Area under the numeric rating scale-time curve
Zeitfenster: 0 to 24 hours postoperatively
|
The area under the numeric rating scale-time curve from 0 to 24 postoperative hours will be calculated separately for pain at rest and during activity using pain scores measured at 0, 3, 6, 12, 18, and 24 hours and the trapezoidal rule. Higher values indicate a greater cumulative pain burden. |
0 to 24 hours postoperatively
|
|
Comprehensive Complication Index
Zeitfenster: Up to 30 days postoperatively
|
Overall postoperative morbidity will be quantified using the Comprehensive Complication Index, which integrates all postoperative complications graded according to the Clavien-Dindo classification into a continuous score ranging from 0 to 100. Higher scores indicate greater overall morbidity. |
Up to 30 days postoperatively
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- SPSIPITM1
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .